Red Light Holland has announced that its U.S.-based partner, Irvine Labs, has secured a 2025 psilocybin quota from the Drug Enforcement Administration, a necessary step toward importing naturally derived psilocybin from the Netherlands into the United States.
With this DEA quota in hand, Irvine Labs is now preparing to apply for an import permit that would allow it to receive psilocybin produced at Red Light Holland’s mushroom cultivation facility in the Netherlands. Once imported, the psilocybin will undergo testing and processing at Irvine Labs’ facility in California, which is both FDA-compliant and registered with the DEA for handling Schedule I substances.
The companies plan to develop shelf-stable microdosing capsules using proprietary dehydration and packaging methods aimed at preserving the integrity and extending the shelf life of psilocybin derived from natural sources. This step marks the first major milestone in their partnership, as both companies work to advance into emerging legal psychedelic markets.
Red Light Holland currently operates in the Netherlands’ legal psilocybin market, where it sells premium truffles and mushroom grow kits. Irvine Labs is licensed to manufacture both prescription and over-the-counter drugs and holds DEA authorization for activities involving psilocybin, psilocin, marijuana, LSD, DMT, and several other Schedule I substances.
The long-term goal of the partnership is to develop a compliant, commercialized psilocybin product for export to global markets and inclusion in pilot programs and clinical trials within the U.S.
